Figure S4. Serial quality of life (QoL) assessments in nicotinamide vs. placebo groups over 2 years. The Eastern Cooperative Oncology Group (ECOG) performance status score (A) is represented on a scale from 0 to 4. All other indicators – namely – (B) sleep, (C) oral intake or appetite, (D) urination and bowel movement, (E) fatigue, (F) pain, (G) dyspnea, (H) anxiety and depression, (I) well-being with family, (J) social activities, and (K) trust in the physician are represented on a scale from 1 to 4, with higher scores indicating better outcomes. Assessments were conducted from the baseline visit, and thereafter, every 2 months for 2 years. Dots indicate mean values, while bars denote standard errors.
Figure S4 A. ECOG score

Mean SE
- Nicotinamide
- Placebo

Visit months

Better
Worse
Figure S4 B. Sleep score
Figure S4 D. Urination and Bowel movement

Visit months

Mean SE
- Nicotinamide
- Placebo
Figure S4 F. Pain or Discomfort

Visit months

Mean SE

Niacinamide
Placebo
Figure S4 G. Dyspnea

Visit months

0 m 2m 4m 6m 8m 10m 12m 14m 16m 18m 20m 22m 24m

Worse Better

Mean SE

Nicotinamide

Placebo
Figure S4 I. Well being with family

- Mean SE
- Nicotinamide
- Placebo

Visit months

Worse — Better

0 m 2m 4m 6m 8m 10m 12m 14m 16m 18m 20m 22m 24m
Figure S4 J. Social activity

Visit months

Worse
Better

Mean SE
Nicotinamide
Placebo